Johnson & Johnson and the University of Queensland's Institute of Molecular Bioscience drug development program will co-develop drugs for the treatment of chronic pain using parts of spider venom, according to a Bloomberg Businessweek report.
The development team will use peptides from spider venom, which can block pain, to create drugs. According to Bloomberg Businessweek, the project team will include University of Queensland researchers Paul Alewood and Glenn King.
Related Articles on Pain Management:
5 Business Practices of Boston PainCare: a Case Study of a Successful Pain Management Practice
Florida Pain Regulations Might Hurt Care for Some Patients in Pain
Scripps Research Institute Scientists Identify Protein that Sends Pain Signals
The development team will use peptides from spider venom, which can block pain, to create drugs. According to Bloomberg Businessweek, the project team will include University of Queensland researchers Paul Alewood and Glenn King.
Related Articles on Pain Management:
5 Business Practices of Boston PainCare: a Case Study of a Successful Pain Management Practice
Florida Pain Regulations Might Hurt Care for Some Patients in Pain
Scripps Research Institute Scientists Identify Protein that Sends Pain Signals